

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

New 2'-O-alkyl-oligo-ribonucleotide(s) with 8-35 nucleotide units - useful as anti-sense oligo-nucleotide(s), primers and probes

Patent Number: DE4110085
Publication date: 1992-10-01
Inventor(s): BRUNAR HELMUT DIPL ING (AT); HOLZNER ARMIN DIPL ING (AT); ISSAKIDES GEORG DIPL ING (AT); KNOLLMUELLER MAX PROF DR (AT); NOE CHRISTIAN DIPL ING DR (AT); BIRNSTIEL MAX PROF DR (AT); COTTEN MATTHEW DR (AT); OBERHAUSER BERND DR (AT); WAGNER ERNST DR (AT); SCHAFFNER GOTTHOLD DR (AT)
Applicant(s):: BOEHRINGER INGELHEIM INT (DE)
Requested Patent: ☐ DE4110085
Application Number: DE19914110085 19910327
Priority Number(s): DE19914110085 19910327
IPC Classification: A61K31/70 ; A61K49/00 ; C07H19/10 ; C07H19/20
EC Classification: C07H21/00C2, C07H19/06E, C07H19/10E, C07H19/16E, C07H19/20
Equivalents:

Abstract

The following are claimed: (A) Prepn. of an oligoribonucleotide (A), based on 8-35 nucleotides of formula (II) (or a 2'-OH or 2'-deoxy deriv.) comprises: (a) linking the corresp. ribonucleotide building blocks in the presence of a coupling agent; and (b) opt. incorporating labelled gps. and/or lipophilic gps. in (A) and opt. cleaving protecting gps.. In (II), B = cytosine, uracil, adenine, guanine or inosine; R = 1-30C alkyl; E1 = a phosphate diester-, methyl phosphonate, phosphoramidate- or phosphorothioate-residue; Provided that (i) at least one R is 2-30C alkyl and (ii) the terminal 3' and 5' positions are an OH gp. (opt. modified by a labelled or lipophilic gp.) or a phosphite ester-, H-phosphonate- or phosphate ester-residue. (B) Prepn. of an oligoribonucleotide (A'), based on 8-35 nucleotides; (C) (A) are new (A'') when the terminal 3' and 5' positions are OH (opt. modified by labelled or lipophilic gps.) or a phosphate ester residue; (D) Prepn. of nucleosides of formula (III) where B'' = opt. protected cytosine, uracil, adenine, guanine or inosine; R'' = 2-30C alkyl when B is opt. protected adenine, otherwise 1-30C. (E) (III) are new (i) when B'' is guanine protected in 6-position by nitrophenylethyl and R'' is methyl, and (ii) when R'' is 2-30C alkyl and B'' is opt. protected cytosine, inosine, uracil or guanine. (F) Alkylated ribonucleotide building blocks are new; and (G) Liposomes, in which are incorporated (A'') modified by 3'-cholesterol or 3'-thiocholesterol, are new. USE - (A'') are useful as antisense oligonucleotides, probes, primers or primer sections. They may be used to inhibit gene expression or virus replication.